Caris Life Sciences Management
Management criteria checks 2/4
Caris Life Sciences' CEO is David Halbert, appointed in Jan 2008, has a tenure of 18.33 years. total yearly compensation is $20.35M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 43.35% of the company’s shares, worth $1.92B. The average tenure of the management team and the board of directors is 8.3 years and 15.6 years respectively.
Key information
David Halbert
Chief executive officer
US$20.4m
Total compensation
| CEO salary percentage | 3.76% |
| CEO tenure | 18.3yrs |
| CEO ownership | 43.4% |
| Management average tenure | 8.3yrs |
| Board average tenure | 15.6yrs |
Recent management updates
Recent updates
Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy Opportunity
Summary Caris Life Sciences' approach pairs molecular profiling, AI, and large clinico-genomic datasets to support oncology diagnostics, therapy selection, and R&D. Its core platforms are the MI Profile and Caris Assure. These contributed to CAI’s strong 2025 revenue growth. CAI clearly benefited from higher reimbursements, better pricing, and rising test volumes in 2025. Similarly, its pipeline adds optionality with the Caris Detect, MI Clarity, and MRD programs for multi-cancer detection and breast recurrence risk. In my view, CAI’s current valuation multiples seem compelling after its post-IPO pullback. As such, I deem CAI a good long-term “Buy” in oncology diagnositcs. Read the full article on Seeking Alpha
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Catalysts About Caris Life Sciences Caris Life Sciences provides comprehensive molecular profiling and data-driven precision medicine solutions across tissue and blood for oncology and related applications. What are the underlying business or industry changes driving this perspective?Caris Life Sciences, Inc.'s (NASDAQ:CAI) Shares May Have Run Too Fast Too Soon
There wouldn't be many who think Caris Life Sciences, Inc.'s ( NASDAQ:CAI ) price-to-sales (or "P/S") ratio of 9.5x is...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$411m |
| Dec 31 2025 | US$20m | US$765k | -US$538m |
| Sep 30 2025 | n/a | n/a | -US$682m |
| Jun 30 2025 | n/a | n/a | -US$799m |
| Mar 31 2025 | n/a | n/a | -US$371m |
| Dec 31 2024 | US$2m | US$750k | -US$378m |
Compensation vs Market: David's total compensation ($USD20.35M) is above average for companies of similar size in the US market ($USD7.11M).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
CEO
David Halbert (69 yo)
Dr. David Dean Halbert, M.D., DSc (h.c.) Founded Caris, Ltd. in 2005 and serves as its General Partner. Dr. Halbert serves as the Chairman, Founder and Chief Executive Officer at U.S.Caris MPI, Inc. (d/b/...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 18.3yrs | US$20.35m | 43.35% $ 1.9b | |
| Executive Vice Chairman & Executive VP | 8.3yrs | no data | 0.19% $ 8.3m | |
| President | 9.5yrs | US$11.58m | 0.19% $ 8.3m | |
| Senior VP | 3.7yrs | US$5.35m | 0.012% $ 525.0k | |
| Senior VP | 9.1yrs | no data | 0.000090% $ 4.0k | |
| Senior VP & Chief Operations Officer | 3.3yrs | no data | no data | |
| Senior VP & CTO | no data | no data | no data | |
| Senior VP & Chief Scientific Officer | 3.3yrs | no data | no data | |
| Senior VP | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Senior Vice President of Human Resources | no data | no data | no data | |
| Executive VP & Chief of Staff at Office of the CEO | no data | no data | no data |
Experienced Management: CAI's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.6yrs | US$20.35m | 43.35% $ 1.9b | |
| Executive Vice Chairman & Executive VP | 8.3yrs | no data | 0.19% $ 8.3m | |
| Lead Independent Director | 18.3yrs | US$647.34k | 3.67% $ 162.9m | |
| Director | 12yrs | US$350.00k | 0.48% $ 21.2m | |
| Independent Director | 18.3yrs | US$359.00k | 0.11% $ 4.9m | |
| Vice Chairman | 18.3yrs | US$350.00k | 0.19% $ 8.3m | |
| Independent Vice Chairman | 16.7yrs | US$350.00k | 0.10% $ 4.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.8yrs | US$412.06k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: CAI's board of directors are seasoned and experienced ( 15.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 05:43 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caris Life Sciences, Inc. is covered by 14 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |